Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
SMAD2 binding regions in triple negative breast cancer cell line, Hs578T
PubMed Full text in PMC Similar studies SRA Run Selector
SMAD2 binding regions in breast cancer cell line and RNA-seq transcriptome analyses in T47D
PubMed Full text in PMC Similar studies
RNA-seq transcriptome analyses in T47D cells treated with ActA and Palbociclib.
PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector
SMAD2 binding regions in estrogen receptor-positive breast cancer cell line, T47D
CDK4/6 inhibitors in ER positive breast cancers
PubMed Full text in PMC Similar studies Analyze with GEO2R
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
Genome wide transcriptome analysis of palbociclib or GSK3326595 treated A375 cells [Palbociclib_GSK_RNASeq]
Gene expression alterations associated with acquired-resistance to the CDK4/6 inhibitor palbociclib [Palbociclib resistance_RNASeq]
Gene expression analyses of palbociclib treated ER+ breast cancer cell lines as assessed by RNA-seq
Breast Cell Lines: Experimental vs. Mixed Reference
Expression data from LncRNA TROJAN knockdown breast cancer cells
Resistance to Palbociclib involves multiple mechanisms amenable to targeting with drug holidays or drug switching to improve therapeutic outcome
Resistance to Palbociclib involves multiple mechanisms amenable to targeting with drug holidays or drug switching to improve therapeutic outcome [Affymetrix]
Resistance to Palbociclib involves multiple mechanisms amenable to targeting with drug holidays or drug switching to improve therapeutic outcome [Illumina]
Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer
High CDK6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor-positive metastatic breast cancer
PD991 Gene Expression Arrays
Estrogen receptor ChIP-seq in response to mTOR inhibition
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to Palbociclib
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to Palbociclib [tumors]
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on